Meijun Hao

528 citations
17 papers · 452 indexed · h-index 11
Topics
Cancer Mechanisms and Therapy (8 papers)Peptidase Inhibition and Analysis (4 papers)Mechanisms of cancer metastasis (3 papers)
Partner nations
ChinaUnited States

In The Last Decade

Meijun Hao

14 papers receiving 452 citations

Peers

Meijun Hao
Comparison fields: 5 of 69
  • Molecular Biology 247
  • Pathology and Forensic Medicine 184
  • Oncology 139
  • Immunology 86
  • Cell Biology 72
Replace Shoupeng Sheng with:
Shoupeng Sheng China
Florian Corvinus Germany
B. Scaglione-Sewell United States
Xinshu Dong China
Xiaotang Yu China
Freya A. Goumas Germany
Shu-Ching Hsieh Taiwan
Meijun Hao relative to Shoupeng Sheng China Shoupeng Sheng's profile →
Citations per field
00.5×3.6×
Shoupeng Sheng · 1×
Citations per year

Countries citing papers authored by Meijun Hao

Since Specialization
Citations

This map shows the geographic impact of Meijun Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meijun Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meijun Hao more than expected).

Fields of papers citing papers by Meijun Hao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meijun Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meijun Hao. The network helps show where Meijun Hao may publish in the future.

Co-authorship network of co-authors of Meijun Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Meijun Hao. A scholar is included among the top collaborators of Meijun Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meijun Hao. Meijun Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
#WorkIndexed citations
1 0
2 0
3 0
4 49
5 50
6 20
7 12
8 22
9 7
10 25
11 47
12 89
13 67
14 21
15 36
16
[Regulation of microRNA-122 on HBV replication by targeting HBx sequence].
6
17
[Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients].
1

About Meijun Hao

Meijun Hao is a scholar working on Pathology and Forensic Medicine, Hepatology and Immunology, having authored 17 papers that have together received 452 indexed citations. Recurring topics across this work include Cancer Mechanisms and Therapy (8 papers), Peptidase Inhibition and Analysis (4 papers) and Mechanisms of cancer metastasis (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (184 citations), Toxicology (31 citations) and Oncology (139 citations). Meijun Hao has collaborated with scholars based in China and United States. Frequent co-authors include Jiasheng Zheng, Xia Wu, Shoupeng Sheng, Caixia Hu, Yu Sun, Long Jiang, Yabo Ouyang, Xicai Sun, Honghai Zhang and Cong Li. Their work appears in journals such as PLoS ONE, Scientific Reports and International Journal of Biological Macromolecules.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026